Why Halozyme Therapeutics, Inc. (HALO) stock moved
Halozyme Therapeutics, Inc. (HALO) shares climbed 6.6% to $116.82 as of October 14, 2026, a significant gain from the prior close of $109.62. BestStocks flagged the session as a major change for HALO. The move is tied to price move up. Below, we break down what changed for HALO, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
HALO climbed 6.6% to $116.82
Halozyme Therapeutics, Inc. (HALO) moved +6.35% from $109.84 to $116.82 on 2026-10-14, reaching a new 30-day high on volume 1.9x the 5-day average. No company-specific news, earnings announcement, or corporate action was found on or immediately before the move date. HALO earnings announcement on 2026-11-02 (date not yet confirmed) and the actual EPS result versus the $2.28 consensus estimate.
What it means for Halozyme Therapeutics, Inc. investors
For Halozyme Therapeutics, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 6.6% price move with conviction. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $106.00, implying -9.3% downside from $116.82. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality medium (65/100). With earnings roughly 19 days out, the next report is the most likely near-term test of the move.
HALO price reaction
HALO last traded at $116.82, up $7.20 (+6.57%) from the previous close of $109.62. The session traded on 1.8× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $106.25 and $116.82, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Halozyme Therapeutics, Inc. (HALO)
The consensus analyst price target on Halozyme Therapeutics, Inc. (HALO) is $106.00, 9.3% below the recent $116.82. Over the past 90 days analysts logged 1 upgrade, 9 maintains, and 0 downgrades. Here is how the bullish and bearish cases on HALO line up.
The bullish case
- The Street's most bullish target is $130.00 (+11.3%).
- 1 analyst upgrade in the past 90 days, most recently Leerink Partners to Outperform (2026-08-07).
- Material positive event.
- Strong 6.6% price move with conviction.
- Halozyme Therapeutics, Inc. (HALO) moved +13.94% from $90.50 to $103.12 on 2026-08-07, reaching a new 30-day high.
The bearish case
- The consensus analyst price target of $106.00 sits 9.3% below the recent $116.82, so the average target sees limited room to run.
- The most bearish analyst target is $90.00 (-23.0%).
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 14, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for HALO
In-depth HALO event analyses
Frequently asked questions about HALO
Why did Halozyme Therapeutics, Inc. (HALO) stock move?
HALO climbed 6.6% to $116.82. The move is associated with price move up.
How much did HALO stock rise?
HALO gained 6.57% ($7.20) versus the prior close of $109.62, last trading at $116.82 on 1.8× average volume.
When is Halozyme Therapeutics, Inc.'s next earnings date?
HALO's next earnings report is estimated for 2026-11-02 — about 19 days away.
What is the analyst price target for HALO?
The consensus analyst price target for HALO is $106.00, about 9.3% below the current $116.82. Over the past 90 days, analysts recorded 1 upgrade, 9 maintains, and 0 downgrades.
How BestStocks tracks HALO
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for HALO, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 14, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.